Multi-omics and artificial intelligence can rank genes, proteins, pathways and molecular states with increasing resolution, yet therapeutic target selection requires a stronger inference than statistical association or predictive relevance. This article develops a causal-reasoning framework for deciding when an omics-supported target claim is sufficiently credible to inform therapeutic progression. The analysis separates five questions that are frequently collapsed: whether the disease-associated signal is assigned to the correct causal gene or molecular entity; whether perturbing that entity is likely to change the disease process in the intended direction; how network structure modifies the consequence of perturbation; whether the mechanism is active in the relevant tissue, cell state and disease stage; and whether disease heterogeneity restricts benefit or introduces harm in particular subgroups. The framework treats actionability as a context-bounded intervention claim rather than a property conferred by cross-omics concordance, network centrality, feature importance or model performance. Evidence can therefore move a target forward, hold it in an exploratory state, restrict it to a conditional domain, or move it backward when counterevidence emerges. The central implication is that multi-omics becomes therapeutically informative only when association is converted into a defensible, revisable account of causal mechanism, intervention direction and context-specific consequence.